PoliticsUnited States of America Preliminary data from a September trial showed the drug slowed cognitive decline by 27% in patients.It also indicated that the treatment risks brain swelling and bleeding among some patients.The US Food and Drug Administration (FDA) on Friday approved a new drug designed to slow cognitive decline in those suffering from Alzheimer's disease.
[
add
]
[
|
|
...
]